| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
|
| [2] |
Ashworth TR.A case of cancer in which cells similar to those in the tumors were seen in the blood after death [J]. Aust Med J, 1869, 14: 146-149.
|
| [3] |
Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme [J]. C R Seances Soc Biol Fil, 1948, 142(3-4): 241-243.
|
| [4] |
U．S. Government. Blood profiling atlas pilot[EB/OL]. [2016-12-10].
URL
|
| [5] |
国家食品药品监督管理总局. 叶酸受体细胞检测试剂盒[EB/OL]. [2016-12-10]．
URL
|
| [6] |
U．S.Food and Drug Administration. Cobas EGFR mutation test v2[EB/OL]. [2016-12-10].
URL
|
| [7] |
Raimondi C, Gradilone A, Naso G, et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients [J]. Breast Cancer Res Treat, 2011, 130(2): 449-455.
|
| [8] |
Grover PK, Cummins AG, Price TJ, et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research [J]. Ann Oncol, 2014, 25(8): 1506-1516.
|
| [9] |
Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction [J]．Cancer Res, 2013, 73(21): 6384-6388.
|
| [10] |
Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis [J]. Cell, 2014, 158(5): 1110-1122.
|
| [11] |
Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis [J]. Nat Rev Cancer, 2011, 11(2): 123-134.
|
| [12] |
Smith HA, Kang Y. The metastasis-promoting roles of tumor-associated immune cells [J]. J Mol Med (Berl), 2013, 91(4): 411-429.
|
| [13] |
Bonecchi R, Galliera E, Borroni EM, et al. Chemokines and chemokine receptors: an overview [J]. Front Biosci (Landmark Ed), 2009, 14: 540-551.
|
| [14] |
Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions [J]. Cancer Lett, 2007, 253(2): 180-204.
|
| [15] |
Mostert B, Sleijfer S, Foekens JA, et al. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer [J]. Cancer Treat Rev, 2009, 35(5): 463-474.
|
| [16] |
Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy [J]. Clin Cancer Res, 2004, 10(24): 8152-8162.
|
| [17] |
Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells [J]. Cell, 2009, 139(7): 1315-1326.
|
| [18] |
Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA [J]. J Clin Oncol, 2014, 32(6): 579-586.
|
| [19] |
Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection [J]. Cell Res, 2014, 24(6): 766-769.
|
| [20] |
Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma [J]. Am J Hum Genet, 1999, 64(1): 218-224.
|
| [21] |
Yong E. Cancer biomarkers: written in blood [J]. Nature, 2014, 511(7511): 524-526.
|
| [22] |
Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors [J]. Proc Natl Acad Sci U S A, 2005, 102(45): 16 368-16 373.
|
| [23] |
Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients [J]. Nat Rev Cancer, 2011, 11(6): 426-437.
|
| [24] |
Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, et al. Cancer progression mediated by horizontal gene transfer in an in vivo model [J]. PLoS One, 2012, 7(12): e52754.
|
| [25] |
Boral D, Vishnoi M, Liu HN, et al. Molecular characterization of breast cancer CTCs associated with brain metastasis [J]. Nat Commun, 2017, 8(1): 196.
|
| [26] |
Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells [J]. Sci Transl Med, 2013, 5(179): 179ra147.
|
| [27] |
Bitting RL, Boominathan R, Rao C, et al. Development of a method to isolate circulating tumor cells using mesenchymal-based capture [J]. Methods, 2013, 64(2): 129-136.
|
| [28] |
Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research [J]. Nat Rev Cancer, 2014, 14(9): 623-631.
|
| [29] |
Pantel K, Deneve E, Nocca D, et al. Circulating epithelial cells in patients with benign colon diseases [J]. Clin Chem, 2012, 58(5): 936-940.
|
| [30] |
Zhou MD, Hao S, Williams AJ, et al. CORRIGENDUM: separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells [J]. Sci Rep, 2015, 5: 7967.
|
| [31] |
Zheng S, Lin HK, Lu B, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood [J]. Biomed Microdevices, 2011, 13(1): 203-213.
|
| [32] |
Harouaka RA, Zhou MD, Yeh YT, et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells [J]. Clin Chem, 2014, 60(2): 323-333.
|
| [33] |
Yu M, Bardia A, Aceto N, et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility [J]. Science, 2014, 345(6193): 216-220.
|
| [34] |
Hughes AD, Mattison J, Western LT, et al. Microtube device for selectin-mediated capture of viable circulating tumor cells from blood [J]. Clin Chem, 2012, 58(5): 846-853.
|
| [35] |
Mu Z, Benali-Furet N, Uzan G, et al. Detection and characterization of circulating tumor associated cells in metastatic breast cancer [J]. Int J Mol Sci, 2016, 17(10)．pii: E1665.
|
| [36] |
Li Y, Zhang X, Ge S, et al. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer [J]. Oncotarget, 2014, 5(16): 6594-6602.
|
| [37] |
Alix-Panabieres C, Pantel K. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay [J]. Expert Rev Mol Diagn, 2015, 15(11): 1411-1417.
|
| [38] |
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage [J]. Nat Med, 2014, 20(5): 548-554.
|
| [39] |
Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing [J]. Cancer Res, 2013, 73(10): 2965-2975.
|
| [40] |
Jordan NV, Bardia A, Wittner BS, et al. HER2 expression identifies functional states within circulating breast cancer cells [J]. Nature, 2016, 537(7618): 102-106.
|
| [41] |
李蕾，刘毅，张少华，等．循环肿瘤细胞检测在不同阶段不同类型乳腺癌中的应用及意义[J]．中华医学杂志，2014, 94(36)：2812-2815.
|
| [42] |
边莉，刘毅，王涛，等．循环肿瘤细胞动态变化对转移性乳腺癌患者治疗反应及预后的预测价值[J]．中华医学杂志，2014，94(4)：265-268.
|
| [43] |
吕海通，施宇梅，安胜利，等．循环肿瘤细胞在可手术乳腺癌患者中的检出率及特征分析[J]．广东医学，2016，37(12)：1819-1822.
|
| [44] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer [J]. N Engl J Med, 2013, 368(13): 1199-1209.
|
| [45] |
Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer [J]. Sci Transl Med, 2015, 7(302): 302ra133.
|
| [46] |
Liao Y, Wang SY, Meng XY, et al. Circulating tumor cells in breast cancer and its association with tumor clinicopathological characteristics: a meta-analysis [J]. Med Oncol, 2014, 31(12): 343.
|
| [47] |
Iwata H, Masuda N, Yamamoto D, et al. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer [J]. Breast Cancer Res Treat, 2017, 162(3): 501-510.
|
| [48] |
Oshiro C, Kagara N, Naoi Y, et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients [J]. Breast Cancer Res Treat, 2015, 150(2): 299-307.
|
| [49] |
Babayan A, Hannemann J, Spötter J, et al. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients [J]. PLoS One, 2013, 8(9): e75038.
|
| [50] |
Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer [J]. Cancer Sci, 2011, 102(1): 1-8.
|
| [51] |
Ibrahim EM, Kazkaz GA, Al-Mansour MM, et al. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis [J]. Breast Cancer Res Treat, 2015, 152(3): 463-476.
|
| [52] |
Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications [J]. Breast Cancer (Dove Med Press), 2015, 7: 111-123.
|
| [53] |
Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells [J]. Mol Oncol, 2015, 9(9): 1773-1782.
|
| [54] |
Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA [J]. Nature, 2013, 497(7447): 108-112.
|
| [55] |
U．S. National Institutes of Health. Medico-economic interest of taking into account circulating tumor cells (CTC) to determine the kind of first line treatment for metastatic, hormone-receptors positive, breast cancers[EB/OL]．[2016-12-10]．
URL
|
| [56] |
U．S. National Institutes of Health. DETECT III - a multicenter, phase III study to compare standard therapy ＋/- lapatinib in HER2-ve MBC-patients with HER2＋ve CTCs (DETECT III) [EB/OL]．[2016-12-10]．
URL
|